Archivio istituzionale della ricerca dell'Università degli Studi di Palermo
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, pubblicazioni, progetti, attività) adottato dall’Università di Palermo, e ha lo scopo di raccogliere, conservare, documentare, e diffondere ad accesso aperto le informazioni relative alla produzione scientifica degli autori afferenti all’Ateneo.
EnglishBAY 81-8973 is an unmodified, full-length third generation recombinant factor VIII (rFVIII) which offers a more favorable pharmacokinetic (PK) profile, compared to its predecessor sucrose-formulated rFVIII (rFVIII-FS). We here report on a retrospective case series of nine patients affected by hemophilia A (HA), with variable disease severity, bleeding phenotype and comorbidities, to underline our clinical practice on prophylaxis with a recently introduced standard hall-life recombinant Factor VIII. The current case series highlights how the current clinical management of hemophilia is able to personalize treatment in several specific conditions like concomitant illnesses with thrombotic risk and allergic reactions.
Santoro, R.C., Giuffrida, G., Daniele, F., Gagliano, F., Mansueto, M.F., Calafiore, V., et al. (2020). Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series. TRANSFUSION AND APHERESIS SCIENCE, 102897 [10.1016/j.transci.2020.102897].
| Data di pubblicazione: | 2020 | |
| Titolo: | Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series | |
| Autori: | ||
| Citazione: | Santoro, R.C., Giuffrida, G., Daniele, F., Gagliano, F., Mansueto, M.F., Calafiore, V., et al. (2020). Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series. TRANSFUSION AND APHERESIS SCIENCE, 102897 [10.1016/j.transci.2020.102897]. | |
| Rivista: | ||
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.transci.2020.102897 | |
| Abstract: | BAY 81-8973 is an unmodified, full-length third generation recombinant factor VIII (rFVIII) which offers a more favorable pharmacokinetic (PK) profile, compared to its predecessor sucrose-formulated rFVIII (rFVIII-FS). We here report on a retrospective case series of nine patients affected by hemophilia A (HA), with variable disease severity, bleeding phenotype and comorbidities, to underline our clinical practice on prophylaxis with a recently introduced standard hall-life recombinant Factor VIII. The current case series highlights how the current clinical management of hemophilia is able to personalize treatment in several specific conditions like concomitant illnesses with thrombotic risk and allergic reactions. | |
| Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| Santoro_Kovaltry_Trasf Apher Journal.pdf | accepted article | Pre-print | Open Access Visualizza/Apri |
http://hdl.handle.net/10447/430607
Copyright © 2021